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Abstract
Microglial cells closely interact with senile plaques in Alzheimer’s disease and acquire the morphological appearance of an
activated phenotype. The significance of this microglial phenotype and the impact of microglia for disease progression have
remained controversial. To uncover and characterize putative changes in the functionality of microglia during Alzheimer’s
disease, we directly assessed microglial behavior in two mouse models of Alzheimer’s disease. Using in vivo two-photon
microscopy and acute brain slice preparations, we found that important microglial functions - directed process motility and
phagocytic activity - were strongly impaired in mice with Alzheimer’s disease-like pathology compared to age-matched
non-transgenic animals. Notably, impairment of microglial function temporally and spatially correlated with Ab plaque
deposition, and phagocytic capacity of microglia could be restored by interventionally decreasing amyloid burden by Ab
vaccination. These data suggest that major microglial functions progressively decline in Alzheimer’s disease with the
appearance of Ab plaques, and that this functional impairment is reversible by lowering Ab burden, e.g. by means of Ab
vaccination.
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Introduction
Microglial cells execute important functions in the brain. They
constantly survey their surrounding and react to acute tissue
injuries [1,2]. In the healthy brain, microglia contact synapses for
seconds, which can be prolonged up to one hour upon acute injury
and eventually leads to the disappearance of the contacted
neuronal structure [3,4]. Microglia are also involved in shaping
adult hippocampal neurogenesis through phagocytosis of apoptotic
newborn neuroblasts [5]. Together, these data highlight that so-
called ‘‘resting’’ microglia in the healthy brain are able to modify
their environment, e.g. by their intrinsic phagocytic activity [6].
In Alzheimer’s disease (AD), microglia are attracted to b-
amyloid (Ab) plaques, produce elevated levels of proinflammatory
cytokines and reactive oxygen species, and exhibit a change in
morphology [7–11]. These phenotypical and morphological
changes of microglia are commonly interpreted as an ‘‘activated’’
state [12,13]. However, microglial activation is not an all-or-none
process and the morphology of microglial cells does not necessarily
match their functional state [14,15].
A number of in vitro studies have not only shown that
administration of Ab stimulates the production of inflammatory
cytokines and activation markers in microglial cells [8] but also
triggers its uptake by receptor-mediated phagocytosis [16]. Further
studies found that microglial cells internalize soluble, protofibrillar
and fibrillar forms of Ab [9,17,18] in vitro and in vivo by several
mechanisms such as macropinocytosis or endocytosis, highlighting
the general aptitude of microglia to remove Ab. However, the
question of whether resident microglia restrict Ab plaque growth
in AD has remained controversial, as the recruitment of microglia
to Ab plaques does not seem to result in their degradation [13,18].
More importantly, we have recently found that temporary ablation
of microglia has no effect on the formation and maintenance of Ab
plaques [19]. Interestingly, expression of receptors and enzymes
involved in microglial Ab-uptake and degradation is progressively
downregulated in a transgenic mouse model of Alzheimer’s disease
[20]. Thus, it has been suggested that microglia are possibly less
efficient in removing and degrading Ab at later stages of
Alzheimer’s disease and become dysfunctional [13,20].
In order to characterize putative progressive AD-associated
changes in microglia not only at an expression level, but also
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functionally, we directly assessed and quantified microglial
phagocytic and directed motile function in AD mouse models
using two-photon microscopy and acute cerebral slice prepara-
tions. Furthermore, we reduced Ab plaque burden in an
Alzheimer’s disease mouse model by administering the Ab-specific
antibody Ab9 and assessed whether this interventional treatment
restores AD-associated functional changes in microglia. Our data
obtained from two different mouse models of Alzheimer’s disease
reveals further insight into specific changes of microglial behavior
during Alzheimer’s disease and suggest that Ab plaque deposition
and microglial function are closely interrelated.
Materials and Methods
Ethics Statement
All procedures involving handling of living animals were
performed in accordance with the German animal protection
law and were approved by the regional offices for health and social
services in Berlin.
Mouse Models
APPPS1 mice, a transgenic mouse model of cerebral amyloidosis
expressing human APP with the Swedish mutation (KM670/
671NL) and human mutated PS1 (PS1-L166P) [21] were kindly
provided by Mathias Jucker, University of Tu¨bingen, Germany.
APP23 mice, which express APP with the Swedish mutation [22]
were provided by Novartis, Basel, Switzerland. For two-photon
imaging experiments Cx3cr1gfp/gfp mice [23] were crossbred to
APPPS1 mice and resulting offspring heterozygous for Cx3cr1GFP
and/or for the APPPS1 transgenes was used for imaging
experiments. Cx3cr1gfp/gfp mice were kindly provided by Frank
Kirchhoff, University of Saarland, Germany. All mice were kept
under standard housing conditions with a 12 h light/dark cycle
and access to standard food and water ad libitum. Throughout this
study transgene-negative littermates were used as controls except
when using APP23 mice, where age-matched wildtype animals
served as controls. Female and male mice were included in the
experiments in an about equal distribution.
Primary Microglial Cell Culture
Microglial cultures were prepared from cerebral cortex of 1–3
day old APPPS1 and wildtype mice as previously described [24]
and cultured in DMEM supplemented with 10% fetal calf serum,
2 mM L-glutamine, 100 units/ml penicillin and 100 mg/ml
streptomycin. After establishment of an astrocytic monolayer,
medium was additionally supplemented with 30% L929-condi-
tioned DMEM (M-CSF-secreting mouse fibroblast cell line) to
stimulate microglial proliferation. After separating microglia from
the underlying astrocytic layer by shaking for one hour at
100 rpm, cells were seeded on glass coverslips at a density of
56104/cover slip. Cultures were used for experiments one day
after plating. Cell-culture media and supplements were purchased
from PAA Laboratories GmbH (Co¨lbe, Germany).
Vaccination Paradigm
Ab9 (mouse anti Ab aa. 1–16 IgG2a k, QED Bioscience Inc.) or
total nonspecific mouse IgG (control, SLM66; Equitech Bio) were
injected intraperitoneally at 500 mg twice a week for 6 weeks in
age-matched APPPS1 mice (n= 3 per group) or WT (n= 2 per
group) starting at 170 days of age.
Preparation of Acute Brain Slices
Mice were decapitated and brains were carefully removed and
washed in artificial cerebrospinal fluid (aCSF) containing (in mM):
NaCl 134; KCl 2.5; MgCl2 1.3; CaCl2 2; K2HPO4 1.25; NaHCO3
26; D-glucose 10; pH 7.4. The buffer solution was saturated with
carbogen (95% O2, 5% CO2). 130 mm thick coronal slices were
prepared using a vibratome (Microm, Walldorf, Germany) at 4uC,
and were kept in brain slice buffer at room temperature (21–25uC)
for 2 h until the phagocytosis experiment was performed.
Assessment of Phagocytosis
To quantify microglial phagocytic activity in acute brain slices,
experiments were performed in APPPS1 and non-transgenic
littermates at 7–9 week and at 4 and 9 month (n= 3–4 per age
group and genotype) of age, as well as in 20 month old APP23
mice and aged-matched wildtype mice (n = 3 per genotype). Acute
brain slices or primary microglial cell cultures (3 independent
experiments) were incubated with a suspension of FCS-coated
Yellowgreen fluorescent carboxylated microspheres (3 mm diam-
eter, Polysciences Europe GmbH) at a concentration of 1.76107
microspheres/ml for 60 min (slices) or 30 min (cell culture) at
37uC, intensively washed and finally fixed with 4% paraformal-
dehyde. Brain sections and microglial cell cultures were stained
with anti-Iba-1 and anti-Ab (4G8) antibodies to visualize microglia
and Ab plaques, respectively.
Immunohistochemistry
Fixed brain slices and primary microglial cells were incubated
with 0.75 mg/ml anti-Iba-1 antibody (Wako) and 0.5 mg/ml 4G8
antibody (Signet). 6.25 mg/ml donkey anti-rabbit Cy3, 2.5 mg/ml
donkey anti-mouse DyLight 649 (Jackson ImmunoResearch) or
4 mg/ml Alexa Fluor 568 goat anti rabbit (Invitrogen) secondary
antibodies were used. After washing, slices were incubated for
30 min with Hoechst 33258 (Sigma-Aldrich; 1:10000) or DRAQ5
(Cell Signalling Technology; 1:1000) in 0.1 M PB and mounted in
Aqua polymount for further analysis using confocal microscopy.
Confocal Microscopy and Quantification of Phagocytosis
Confocal laser scanning microscopy was performed on Leica
SPE and Zeiss LSM5 Exciter confocal microscopes with LAS AF
and ZEN 2008 software, respectively. In brain sections derived
from acute brain slices z-stacks of 20 mm thickness were performed
using a 40x objective with a step size of 1 mm beginning from the
top of the slice, where the microspheres are located. Beads per cell
were counted using Image J MacBiophotonics cell counter plugin
ensuring that only beads inside a cell were counted as positive. The
phagocytic index was determined by assessing the percentage of
cells which contained 0, 1–4, 5–7, 8–10 and.10 microspheres per
cell. The percentage of cells in each group was multiplied by the
corresponding grade of phagocytosis (1–4:1, 5–7:2, 8–10:3,
.10:4). The sum of the products in each group was then termed
and displayed as phagocytic index [25]. 4–15 ROIs (i.e. fields of
view) were analyzed per animal.
Plaque Load Assessment
Brain sections were incubated in 0.001% Thiazine Red (Sigma)
solution in 0.1 M PB, thereby labeling the b-sheet structure of
dense core plaques [26]. Thiazine Red-positive plaques were
quantified by scanning cerebral sections with a Nikon Ti Epsilon
microscope using a TRITC FL-filter set and fixed acquisition
settings. Large images of whole coronal brain section were
obtained by stitching single images using NIS Elements software.
Coverage of respective brain area (cortex, hippocampus, cerebel-
lum) by Thiazine Red-positive plaques was quantified by
analyzing images using Image J with a fixed intensity threshold.
Staining artifacts were manually removed prior to analysis. 3–4
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whole coronal brain sections were analyzed per animal and
respective brain region.
Two-photon Imaging of Acute Brain Slices
300 mm thick acute coronal slices were prepared from 10 month
oldmice(3micepergenotype)andstainedwith0.001%ThiazineRed
in aCSF for 10 min before imaging experiment. Imaging was
performed with a two-photon laser scanning microscope directly
coupledtoaChameleonultrafast laser (Coherent). Inorder tocreatea
discrete laser lesion, the laserwas focused at235 mmdepths from the
surface of the z-stack at a wavelength of 800 nm until autofluores-
cence was visible. In APPPS1-Cx3cr1+/gfp mice laser lesions were
placed next to an Ab plaque with a maximum distance to a
neighboringThiazineRed-positiveplaqueof80 mm.Formonitoring
microglial responses 60 mm z-stacks were imaged with a step size of
3 mm covering a field of 307.26307.2 mm every minute for 60 min.
Recordings were analyzed with Image J MacBiophotonics, as
adapted from Davalos et al. 2005 [2]. For calculating the average
microglial response 7 (Cx3cr1+/gfp) or 8 (APPPS1-Cx3cr1+/gfp) ROIs
from 4 mice per genotype were analyzed.
In vivo Imaging
For intravital imaging, b-amyloid plaques were labeled with
methoxy-XO4 (10 mg/kg) as described [27]. Methoxy-XO4 was
kindly provided by William Klunk, University of Pittsburgh, USA.
Before surgery mice were anesthetized by i.p. injection of a xylazine
and ketamine mix in physiological saline (9.2 and 131 mg/kg body
weight correspondingly). At approximately the center of the parietal
bone a small cranial window with a 1.5–2 mm diameter (corre-
sponding to an area of 1.8–3 mm2) was prepared using a high-speed
dental drill. A circular bone fragment was carefully removed and the
duramater was left intact. Focal lesion and time-lapse recording was
started 30 min after the surgical procedure to ensure absence of
bleeding. All in vivo recordings weremade in a time interval between
30 minand8 hafter the surgicalprocedure.Theskullwas fixed to the
microscope stage and aCSF was placed into the chamber to allow
imaging using a water-immersion objective (20x, NA 0.95, WD
2 mm;Olympus, Germany). Imaging was performed by a commer-
cially availablemultiphoton imaging system(TriMScopeI,LaVision
BioTec,Germany), equippedwithaTi:Sa laser (ChameleonUltra II,
Coherent). Fluorescence (GFP excitation wavelength 920 nm,
methoxy-XO4 excitation wavelength 800 nm) was collected by
three non-descanned PMT-detectors using dichroic mirrors and
three interference filters (593/40 nm, 525/50 nm and 447/40 nm).
XYZ-Stacks were collected every minute with a z-plane distance of
2 mm at a frequency of 400 Hz covering a depth range of 20 mm to
80 mm. The focal laser lesion was applied at a depth of 60 mm by
steering the laser spot to the center of the field of view and irradiating
for 300 ms with 50 mW energy at 920 nm.Microglial response was
analyzed as described above with 8 (Cx3cr1+/gfp) and 6 (APPPS1-
Cx3cr1+/gfp) ROIs from 3mice per genotype.
Statistical Analysis
Data sets were tested for normality by Shapiro-Wilks Test using
SPSS. Two-sided levels of significance were determined by using
the non-parametric Mann-Whitney-U- Test or the parametric T-
Test according to the distribution and are depicted as *p,0.05,
**p,0.01, ***p,0.001. Data are presented as mean 6 s.e.m. For
statistical analyses matching regions of interest (ROI) of multiple
acute brain slices or cell cultures derived from various mice per
experimental group were assessed as indicated and analyzed in a
standardized fashion.
Results
Directed Microglial Process Motility Towards Acute Tissue
Lesion is Impaired in Transgenic AD Mice
Microglia respond to defined tissue injuries by extending their
processes towards the lesion in an ATP-dependent fashion [2]. We
usedthiscanonical functionofmicrogliaasameasuretoevaluatetheir
functionality in an AD mouse model in vivo by intravital time-lapse
two-photonmicroscopy.Notably, theability ofmicroglia fordirected
extensionof theirprocesses towardsa lesionwas largely reduced inAb
plaque carrying APPPS1-Cx3cr1+/gfp mice (Fig. 1A and B and
Videos S1 andS2), whichwere obtained by crossbreedingAPPPS1
mice, a mouse model of cerebral amyloidosis [21] with Cx3cr1gfp/gfp
mice [23], a mouse model that allows visualization of microglia. Ab
plaques were labeled by intraperitoneal injection of Methoxy-XO4
[27]. Whereas microglia from 8 month old Cx3cr1+/gfp control
animals moved their processes towards the laser-induced injury with
an average peak response of 2.4460.6 arbitrary units (a.u.), we only
detected a sparse response of microglia in 8 month old APPPS1-
Cx3cr1+/gfp mice, which harbor a substantial Ab burden at that age
(average peak response of 0.4460.22 a.u., Fig. 1A and B). Since in
situ experiments using acute cerebral slices allow stringent quantifi-
cation of microglial response in a high number of experiments, we
additionally conducted two-photon microscopy studies in acute
coronal cerebral slices. Here, microglia exhibited slightly slower but
otherwise similar process motility towards the lesion as compared to
in vivo experiments. Importantly, microglial response towards the
laser lesion in acute cerebral slices from 10 month old Ab plaque-
carrying APPPS1-Cx3cr1+/gfp mice were significantly reduced com-
pared to their Cx3cr1+/gfp littermates (Fig. 1C and D, Videos S3
and S4). Together, these data indicate that lesion-directed process
extension as a typical functional feature of microglia is severely
impaired in APPPS1mice that harbor Ab plaques.
Phagocytic Activity of Cortical Microglia is Impaired in
APPPS1 and APP23 Mice
We next aimed to investigate another key function of microglia -
their phagocytic capacity. Since directed microglial process
motility was similarly impaired when assessed intravitally or in
acute cerebral slices derived from APPPS1 mice, we reasoned that
defined microglial functions are adequately reflected in acute
cerebral slice preparations. As microglia in different brain regions,
including cerebellum and hippocampus, can be readily evaluated
with this in situ method, we used cerebral slice preparations to
investigate microglial phagocytic capacity and quantified uptake of
fluorescent polystyrene microparticles by microglia of APPPS1
mice as described previously [25]. Likewise to the impaired
directed process extension, microglial phagocytic activity in 9
month old APPPS1 mice was significantly reduced when compared
to wildtype littermates (Fig. 2A).
Mutations of PS1 have been suggested to influence the
phagocytic activity of cells [28,29]. To prove that functional
decline of microglia is a general feature of AD pathology, and to
exclude an impact of the PS1 transgene on microglia in APPPS1
mice unrelated to amyloid pathology, we assessed microglial
phagocytic activity in APP23 mice, a transgenic mouse model of
cerebral amyloidosis that is based on transgenic expression of APP
with the Swedish mutation [22], but not of mutated PS1. Again,
using in situ quantification of microglial phagocytosis, we detected
a drastic impairment of microglial phagocytic activity in APP23
mice (Fig. 2B). While we formally cannot exclude an – overall
rather unlikely - impact of the APP-transgene on the performance
of microglia from APP23 mice, these data indicate that microglial
dysfunction occurs in cerebral amyloidosis mouse models irre-
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spective of the transgenic strain used and, thus, is dependent on
cerebral amyloidosis.
Impairment of Microglial Phagocytic Capacity Correlates
Temporally and Spatially with the Appearance of Plaques
To test whether the observed impairment of microglial
phagocytosis depends on Ab plaque deposition, we compared
microglial phagocytosis in 7–9 week old APPPS1 mice that had not
yet developed detectable amyloid plaque burden to 7–9 week old
APPPS1 mice that showed first cortical amyloid plaques (Fig. 3A
and Fig. S1), as detected by 4G8 immunohistochemistry or
Thiazine Red staining. Importantly, in slices prepared from 7–9
week old APPPS1 mice lacking cortical plaque load, microglial
phagocytosis was as efficient as in wildtype littermates. However,
we observed a significant reduction in phagocytosis in acute slices
from 7–9 week old APPPS1 mice that showed first cortical amyloid
plaques (Fig. 3A). In slices from 4 month old APPPS1 mice with
significant cortical plaque load (Fig. 3A and Fig. S1), impairment
of microglial phagocytosis was already similar to 9 month old
APPPS1 mice (Fig. 3A). Overall, relative microglial phagocytic
activity and cortical Ab plaque burden exhibited a significant
inverse correlation with a Spearman’s correlation coefficient of r
(rho) =20.75 (p = 0.0014, Fig. 3B).
To further establish the interconnection of Ab plaque appear-
ance and microglial dysfunction, we investigated microglial
phagocytosis in various brain regions of APPPS1 mice differing
in the onset of plaque deposition [21]. In plaque-bearing cortices
of 7–9 week old APPPS1 mice, phagocytic activity was impaired,
whereas it was normal in still plaque-free hippocampi of the same
APPPS1 animals (Fig. 3C and Fig. S1). Moreover, phagocytic
capacity was impaired in hippocampi from 4 month old APPPS1
mice, when plaques were present in that region. Importantly, in
the cerebellum, which is devoid of plaques even in aged APPPS1
mice ([21] and Fig. S1), phagocytic capacity remained unaltered
also at 4 months of age (Fig. 3D).
Furthermore, we did not observe a significant difference in the
phagocytic capacity of primary microglia derived from non-
transgenic or APPPS1 mice at postnatal day 1–3, i.e. prior to
plaque deposition (Fig. 3E), indicating that impairment of
phagocytosis is acquired in the presence of Ab plaques over time.
Ab-plaque Load Reduction by Anti-Ab Antibody
Administration Restores Microglial Phagocytic Capacity
in APPPS1 Mice
Finally, we investigated whether the functional impairment of
microglia in plaque-bearing AD mice is reversible by interventions
aimed at lowering Ab burden. One way to counteract progressive
Ab plaque deposition is Ab vaccination resulting in reduced
plaque burden and increased number of Ab-laden microglia in the
cortex of AD patients [30]. Additionally, clearance of amyloid
Figure 1. Lesion-directed microglial process movement is impaired in a mouse model of cerebral amyloidosis. (A) Representative
intravital two-photon microscopy images and (B) time course of microglial process movement towards a laser-induced micro-lesion (dashed circle) in
8 month old live anaesthetized APPPS1-Cx3cr1+/gfp (n = 6) and Cx3cr1+/gfp mice (n = 8). Ab plaques are stained with Methoxy-XO4 (blue, *). (C)
Representative images and (D) relative microglial response to laser lesions in acute cortical cerebral slices of 10 month old APPPS1-Cx3cr1+/gfp (n = 8)
and Cx3cr1+/gfp (n = 7) mice. Ab plaques are stained with Thiazine Red (red, *). Data are mean 6 s.e.m, *p,0.05. Scale bars: 10 mm. a.u. = arbitrary
units.
doi:10.1371/journal.pone.0060921.g001
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deposits and increase in microglial response was observed by in vivo
imaging after stimulation with Ab-specific antibodies when
administered directly to an open skull preparation in a mouse
model of AD [31].
Amyloid plaque burden was therefore reduced in 5 month old
plaque-carrying APPPS1 mice by passive Ab vaccination admin-
istering the anti-Ab antibody Ab9 [32] biweekly for six weeks. This
treatment significantly diminished Thiazine Red-stained dense
core plaques in the hippocampus of APPPS1 mice, while there was
no significant reduction of amyloid in the cortex when compared
to control IgG-treated APPPS1 littermates (Fig. 4B left, 4A left).
Strikingly, in accordance with the regional reduction in cerebral
amyloid plaques, microglial phagocytic activity, measured in acute
cerebral slices, was restored to levels found in Ab9- or IgG-treated
wildtype mice exclusively in the hippocampus (Fig. 4B right). In
contrast, microglial cells in the cortex, which lacked a substantial
decrease in amyloid plaque burden, were still dysfunctional
(Fig. 4A right). Thus, microglial dysfunction is not irreversibly
impaired by Ab plaque deposition, but can be restored during the
course of disease.
Discussion
The Ab plaque-associated functional decline of microglia we
have shown here may explain why temporary ablation of
microglia for up to 30 days in APPPS1 mice does not change the
formation and maintenance of Ab burden [19]. Our findings may
also give an explanation as to why microglia fail to sufficiently
remove Ab plaques in AD in vivo [18,20], and would support the
notion of a dystrophic rather than an activated phenotype of
microglia at late stages of AD [33].
Our methodological approach to quantify phagocytosis extends
existing data on the function of AD-associated microglia during
disease progression. It allowed us to overcome restrictions of
current approaches including (i) the ex vivo analysis of isolated
microglia whose functionality could be disturbed by the isolation
procedure per se, (ii) post-mortem studies, which are stationary,
typically restricted to defined time points, and do not provide
direct information about cellular functionality or (iii) in vivo
imaging studies that are typically limited to superficial cortical
brain areas.
Mechanistically, Ab may directly affect microglial function, as
we were able to detect a significant inverse correlation between Ab
plaque burden and microglial phagocytic activity. Further studies
will be required to address the question, of what kind of Ab species
may be responsible for inducing microglial dysfunction.
A large number of in vitro studies have shown that microglial
cells release a battery of proinflammatory mediators, including
nitric oxide and tumor necrosis factor alpha (TNFa), when
stimulated with Ab peptides [34–36]. Such chronic production of
inflammatory molecules by microglia and/or constant exposure to
a proinflammatory microenvironment within plaque-bearing AD
brains may present another explanation of why microglial function
may be influenced negatively [13,37,38]. This hypothesis is also
supported by the finding that microglia stimulation with the
proinflammatory cytokine TNFa leads to a downregulation of
receptors involved in Ab binding and degradation and reduces
phagocytosis of Ab in vitro [20].
To investigate a second biologically relevant microglial function
we studied process motility by assessing process extensions towards
an acute injury induced by a laser lesion [1,2]. Our results
obtained from in vivo observations were similar to data retrieved by
us in acute brain slices with respect to speed and quantity of lesion-
directed process movements. The significant decrease in the
amount of microglial processes sent towards the injury site, which
we consistently found both in vivo and in situ, supports a report on
impaired baseline dynamics of plaque-associated microglia [27].
However, another detailed analysis of baseline microglial process
turnover in APPPS1 mice has shown that turnover speed of
processes in microglia near plaques (within 50 mm from the plaque
surface) was similar compared to microglia in non-transgenic
animals. Only process speed in microglia directly on Ab plaques
was slightly but significantly reduced [9].
Notably, we show that functional impairment of microglial
phagocytosis can be reversed to non-diseased aptitude by reducing
amyloid by Ab vaccination. This speaks against microglial
senescence as the main underlying mechanism for the decline in
microglial function demonstrated herein. Microglial senescence
has been described in the human brain during aging and in
Alzheimer’s disease and is associated with telomere shortening and
reduced telomerase activity [39]. In contrast to the microglial
phenotype reported here, cellular senescence is irreversible, at least
in lymphocytes and at late stages of cellular senescence [40].
However, similar mechanisms might be involved in inducing
microglial dysfunction and have to be investigated in future
Figure 2. Phagocytic capacity of cortical microglia is impaired
in two mouse models of cerebral amyloidosis. (A) Representative
images (left) and microglial phagocytic index (in arbitrary units, a.u.,
right) of 9 month old APPPS1 mice and wildtype littermate controls (3
mice per genotype; p,0.001). Images show microglia (Iba-1, red), Ab
(4G8, blue) and fluorescent microspheres (green). Orthogonal views of
z-stack images are shown in the bottom panel. (B) Representative
images (left) and microglial phagocytic index of 20 month old APP23
and age-matched control mice (3 mice per genotype, p,0.001, right)
are shown. Data are mean 6 s.e.m, ***p,0.001. Scale bars: 10 mm.
doi:10.1371/journal.pone.0060921.g002
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studies. Furthermore, microglial senescence may play an impor-
tant role in humans during aging.
These data highlight the interrelation of plaque deposition and
microglial behavior, thus expanding the possible modes of action
of other amyloid-reducing approaches to rescuing microglial
function. Such view is in line with a recent report on bexarotene-
mediated reduction of Ab burden, which resulted in an
improvement in neuronal function and, importantly, increased
the number of Ab-laden microglia [41].
Taken together, our data demonstrate that microglial dysfunc-
tion develops early in the course of AD in an Ab-dependent
fashion and can be restored by interventional anti-Ab approaches,
such as Ab vaccination. Our findings therefore suggest that novel
treatment strategies aimed at maintaining or increasing microglial
Figure 3. Impairment of microglial phagocytosis in APPPS1 mice correlates with Ab plaque deposition. (A) Ab plaque load (brain area
covered by Thiazine red-positive plaques) and relative microglial phagocytic activity normalized to corresponding wildtype littermate in the cortex of
7–9 week, 4 and 9 month old APPPS1 mice. 7–9 week old mice were sub-classified according to apparent 4G8 positive plaque deposition as with (+)
or without (2) detectable plaque load. (B) Correlation between extent of plaque load and relative microglial phagocytic activity in the cortex of
APPPS1 mice. (C, D) Thiazine red-covered area and relative phagocytic activity of microglia in the hippocampus of 7–9 week and 4 month old mice
(C) and in the cerebellum of 4 month old APPPS1 mice (D). Absolute values of microglial phagocytic indices from APPPS1 mice were normalized to
wildtype littermate controls (3–4 mice per age group and genotype, ***p,0.001). (E) Phagocytic index (3 independent experiments, p = 0.181) and
representative images of primary microglial cultures from wildtype and APPPS1 mice. Microglia (Iba-1, red), nuclei (DRAQ5, blue) and microspheres
(green). All data are mean 6 s.e.m, *p,0.05, **p,0.01. a.u. = arbitrary units. Scale bars: 10 mm.
doi:10.1371/journal.pone.0060921.g003
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function may represent an attractive therapeutic approach even at
advanced stages of AD.
Supporting Information
Figure S1 Age- and brain area-dependent Ab plaque load in
APPPS1 mice. Representative confocal images of fixed and stained
acute coronal brain slices from APPPS1 mice of the indicated age
showing cortex (a), hippocampus (b) or cerebellum (c). Microglia
(Iba-1, red), Ab plaques (Thiazine Red, green) and nuclei (Hoechst
33258; blue). Scale bars: 50 mm.
(TIF)
Video S1 Rapid microglial response toward an acute laser lesion
in Cx3cr1+/gfp mice. Intravital time-lapse two-photon microscopy
over a period of 36 min shows rapid microglial response upon a
laser lesion in 8 month old Cx3cr1+/gfp mice.
(AVI)
Video S2 Impaired microglial response toward an acute laser
lesion in APPPS1-Cx3cr1+/gfp mice. Intravital time-lapse two-
photon microscopy over a period of 54 min shows attenuated
response of microglial processes (green) toward a laser lesion in 8
month old APPPS1-Cx3cr1+/GFP mice. Ab plaques are stained with
Methoxy-XO4 (blue).
(AVI)
Video S3 Rapid microglial response to a laser-induced lesion in
an acute cerebral slice from Cx3cr1+/gfp mice. Time-lapse two-
photon microscopy of an acute cerebral slice from 10 month old
Cx3cr1+/gfp mice over a time period of 60 min displays rapid
microglial process accumulation around a laser-induced lesion.
(AVI)
Video S4 Microglial response to a laser-induced lesion is
impaired in acute brain slices from APPPS1-Cx3cr1+/gfp mice.
Time-lapse two-photon microscopy of an acute cerebral slice from
10 month old APPPS1-Cx3cr1+/gfp mice over a period of 60 min
shows impaired accumulation of microglial processes around a
laser-induced tissue lesion. Ab plaques are stained with Thiazine
Red (red).
(AVI)
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